|
Carcinoma, Ovarian Epithelial
|
0.050 |
Biomarker
|
disease |
BEFREE |
Key inclusion criteria were prospective clinical trials examining platinum-based NACT for stage II-IV epithelial ovarian cancer.
|
31818526 |
2019 |
|
Epithelial ovarian cancer
|
0.040 |
Biomarker
|
disease |
BEFREE |
Key inclusion criteria were prospective clinical trials examining platinum-based NACT for stage II-IV epithelial ovarian cancer.
|
31818526 |
2019 |
|
Cervix carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Expression of thioredoxin 1 and peroxiredoxins in squamous cervical carcinoma and its predictive role in NACT.
|
31470801 |
2019 |
|
Carcinoma, Ovarian Epithelial
|
0.050 |
Biomarker
|
disease |
BEFREE |
To evaluate the impact of an evidence-based triage algorithm to decide between primary debulking surgery (PDS) and neoadjuvant chemotherapy followed by interval debulking surgery (NACT/IDS) for advanced epithelial ovarian cancer (EOC).
|
31402165 |
2019 |
|
Epithelial ovarian cancer
|
0.040 |
Biomarker
|
disease |
BEFREE |
To evaluate the impact of an evidence-based triage algorithm to decide between primary debulking surgery (PDS) and neoadjuvant chemotherapy followed by interval debulking surgery (NACT/IDS) for advanced epithelial ovarian cancer (EOC).
|
31402165 |
2019 |
|
Neoplasms
|
0.020 |
AlteredExpression
|
group |
BEFREE |
However, breast and node tumor sizes before and after NACT were negatively correlated with hormone receptor conversion and positively correlated with Ki-67 conversion (P < 0.05).
|
31006089 |
2020 |
|
Neoplasm, Residual
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
The dissimilar spatial association of TILs and TIL subtypes with clinicopathological parameters, NACT response and minimal residual disease underlines the necessity of detailed TIL analysis for a better understanding of immune modulatory processes.
|
30717704 |
2019 |
|
Pendred's syndrome
|
0.010 |
Biomarker
|
disease |
BEFREE |
According to residual disease we found no significant differences in term of OS between NACT + IDS patients with residual disease = 0 and PDS patients with residual disease = 0 or residual disease = 1, as well as no significant differences in PFS were found comparing NACT + IDS patients with residual disease = 0 and PDS patients with residual disease = 0; contrarily, median PFS resulted significantly lower in PDS patients receiving optimal debulking (residual disease = 1) in comparison to NACT + IDS patients receiving complete debulking (residual disease = 0).
|
30210049 |
2018 |
|
Pigment dispersion syndrome (disorder)
|
0.010 |
Biomarker
|
disease |
BEFREE |
According to residual disease we found no significant differences in term of OS between NACT + IDS patients with residual disease = 0 and PDS patients with residual disease = 0 or residual disease = 1, as well as no significant differences in PFS were found comparing NACT + IDS patients with residual disease = 0 and PDS patients with residual disease = 0; contrarily, median PFS resulted significantly lower in PDS patients receiving optimal debulking (residual disease = 1) in comparison to NACT + IDS patients receiving complete debulking (residual disease = 0).
|
30210049 |
2018 |
|
Kidney Calculi
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
The results obtained from the renal expression of NaDC1 could explain an adaptive mechanism to prevent the formation of kidney stones by increasing the levels of citrate, a calcium chelator.
|
30140954 |
2018 |
|
Nephrolithiasis
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
The results obtained from the renal expression of NaDC1 could explain an adaptive mechanism to prevent the formation of kidney stones by increasing the levels of citrate, a calcium chelator.
|
30140954 |
2018 |
|
Ureteral obstruction
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Moreover, the urinary excretion of NaDC1 increased after short times of ureteral obstruction (BUO1 and BUO2) and was positively correlated with the time elapsed after obstruction.
|
30140954 |
2018 |
|
Obstructive nephropathy
|
0.010 |
Biomarker
|
disease |
BEFREE |
Renal expression and urinary excretion of Na<sup>+</sup>/dicarboxylate cotransporter 1 (NaDC1) in obstructive nephropathy: a candidate biomarker for this pathology.
|
30140954 |
2018 |
|
Malignant neoplasm of breast
|
0.040 |
Biomarker
|
disease |
BEFREE |
The aim of our study was to estimate of different CTC subsets in breast cancer during the NACT (neoadjuvant chemotherapy).
|
29565320 |
2018 |
|
Breast Carcinoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
The aim of our study was to estimate of different CTC subsets in breast cancer during the NACT (neoadjuvant chemotherapy).
|
29565320 |
2018 |
|
Carcinoma, Ovarian Epithelial
|
0.050 |
Biomarker
|
disease |
BEFREE |
We aimed to performed a meta-analysis and systematic review on the role of neoadjuvant chemotherapy followed by interval debulking surgery (NACT-IDS) in advanced ovarian cancer (AOC) patients.
|
29492221 |
2018 |
|
ovarian neoplasm
|
0.010 |
Biomarker
|
disease |
BEFREE |
We aimed to performed a meta-analysis and systematic review on the role of neoadjuvant chemotherapy followed by interval debulking surgery (NACT-IDS) in advanced ovarian cancer (AOC) patients.
|
29492221 |
2018 |
|
Malignant neoplasm of ovary
|
0.010 |
Biomarker
|
disease |
BEFREE |
We aimed to performed a meta-analysis and systematic review on the role of neoadjuvant chemotherapy followed by interval debulking surgery (NACT-IDS) in advanced ovarian cancer (AOC) patients.
|
29492221 |
2018 |
|
Carcinoma, Ovarian Epithelial
|
0.050 |
GeneticVariation
|
disease |
BEFREE |
For patients with advanced stage epithelial ovarian cancer (EOC), substantial emphasis has been placed on diagnostic tests that can discern which of two treatment options - primary cytoreductive surgery (PCS) or neoadjuvant chemotherapy followed by interval cytoreductive surgery (NACT+ICS) - optimizes patient-level outcomes.
|
29486993 |
2018 |
|
Epithelial ovarian cancer
|
0.040 |
GeneticVariation
|
disease |
BEFREE |
For patients with advanced stage epithelial ovarian cancer (EOC), substantial emphasis has been placed on diagnostic tests that can discern which of two treatment options - primary cytoreductive surgery (PCS) or neoadjuvant chemotherapy followed by interval cytoreductive surgery (NACT+ICS) - optimizes patient-level outcomes.
|
29486993 |
2018 |
|
Malignant neoplasm of breast
|
0.040 |
Biomarker
|
disease |
BEFREE |
Our findings confirm that phenotypic alterations in breast cancer occur after NACT, and that these changes are more pronounced for hormone receptors (especially PR); Significant NACT-associated alterations were not apparent for HER2/neu.
|
29146052 |
2017 |
|
Breast Carcinoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
Our findings confirm that phenotypic alterations in breast cancer occur after NACT, and that these changes are more pronounced for hormone receptors (especially PR); Significant NACT-associated alterations were not apparent for HER2/neu.
|
29146052 |
2017 |
|
Malignant Neoplasms
|
0.020 |
GeneticVariation
|
group |
BEFREE |
The aim of this study was to determine the proportion of patients with advanced ovarian and related cancers (EOC+RC), treated with neoadjuvant chemotherapy and interval debulking surgery (NACT - IDS), and to determine if there was any relationship with optimal cytoreduction rates and overall survival (OS) in a state-wide gynaecologic oncology service over time.
|
28718942 |
2017 |
|
Malignant Neoplasms
|
0.020 |
Biomarker
|
group |
BEFREE |
Surgical and survival outcomes were compared between three treatment groups: patients without high tumor dissemination (HTD) who underwent primary debulking surgery (PDS group); patients with HTD who underwent DLS (DLS group); and patients with HTD diagnosed by cytological confirmation of malignancy followed by neoadjuvant chemotherapy (NACT group).
|
28701190 |
2017 |
|
Primary malignant neoplasm
|
0.010 |
Biomarker
|
group |
BEFREE |
Surgical and survival outcomes were compared between three treatment groups: patients without high tumor dissemination (HTD) who underwent primary debulking surgery (PDS group); patients with HTD who underwent DLS (DLS group); and patients with HTD diagnosed by cytological confirmation of malignancy followed by neoadjuvant chemotherapy (NACT group).
|
28701190 |
2017 |